By Ludwig Burger
FRANKFURT, March 25 (Reuters) - Novo Nordisk said it plans to seek coverage by Germany's public health insurance scheme for the use of its Wegovy drug to cut the risk of strokes and heart attacks, if the drug's extended indication wins European approval.
(Reporting by Ludwig Burger; editing by Jason Neely)
ResMed stock jumped Friday after crushing sales estimates and wiping out worries that weight-loss drugs would squeeze sleep apnea device sales.
Friday, the FDA approved Pfizer Inc’s (NYSE:PFE) Beqvez (fidanacogene elaparvovec-dzkt) for moderate to severe hemophilia B in adult patients who currently use factor IX (FIX) prophylaxis therapy or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var capsid. Beqvez is a one-time treatment designed to enable hemophilia B patients to produce FIX themselves
The risk at these companies is above average, and they're sure to remain volatile. This volatility, however, includes explosively bullish potential.
The FDA approved Pfizer's hemophilia gene therapy on Friday. But Pfizer stock only inched ahead on the approval early Friday.
The U.S. birth rate from 2023 was down 2% from 2022, according to the Centers for Disease Control and Prevention.
Gilead stock pared its gains Friday after beating first-quarter sales forecasts on the back of its Covid treatment, Veklury.
The IRA adds another hurdle to an already challenging research landscape, according to a study from the Pioneer Institute.
Merck (MRK), Sanofi (SNY), Novartis (NVS) and AstraZeneca (AZN) announce their first-quarter results.
Some companies, however, reported a market capitalisation decline, including Gilead Sciences and Roche.
With the US obesity rate hovering at around 40%, tens of millions of Americans could take GLP-1 drugs over the next few years.